Letters to the Editor
Vol. 18 No. 1 (2026): Mediterranean Journal of Hematology and Infectious Diseases
Interpreting MRD and Chimerism After Allogeneic Transplantation for Acute Leukemia
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: September 1, 2026
0
Views
0
Downloads
Authors
Not applicable
Downloads
Download data is not yet available.
Citations
1. Öksüz SBT, Seval GC, Dalva K, Toprak SK. Post-transplant relapse in acute leukemia: comparative value of MRD and chimerism. Mediterr J Hematol Infect Dis. 2026;18(1):e2026028. https://doi.org/10.4084/MJHID.2026.028
2. Loke J, McCarthy N, Jackson A, Siddique S, Hodgkinson A, Mason J, Crawley C, Gilleece M, Peniket A, Protheroe R, Kirkland K, Craddock C. Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS. Blood Adv. 2023;7(14):3666-3676. https://doi.org/10.1182/bloodadvances.2022009493
3. Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Cloos J. 2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138(26):2753-2767. https://doi.org/10.1182/blood.2021013626
4. Cloos J, Valk PJM, Thiede C, Döhner K, Roboz GJ, Wood BL, Walter RB, Wang S, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw D, Kern W, Kim DDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bücklein V, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon R, Heuser M. 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party. Blood. 2026;147(11):1147-1167. https://doi.org/10.1182/blood.2025031480
5. Iacobelli S; EBMT Statistical Committee. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48(Suppl 1):S1-S37. https://doi.org/10.1038/bmt.2012.282
6. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. J Clin Epidemiol. 2013;66(6):648-653. https://doi.org/10.1016/j.jclinepi.2012.09.017
7. Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963-2969. https://doi.org/10.1200/JCO.2013.49.5283
Ethics Approval
Hematology, allogeneic hematopoietic stem cell transplantation, Acute leukemiaSupporting Agencies
NoneHow to Cite
“Interpreting MRD and Chimerism After Allogeneic Transplantation for Acute Leukemia” (2026) Mediterranean Journal of Hematology and Infectious Diseases, 18(1), p. e2026068. doi:10.4084/MJHID.2026.068.
Copyright (c) 2026 Naif AlJohani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
